ATE213155T1 - Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis - Google Patents

Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis

Info

Publication number
ATE213155T1
ATE213155T1 AT94914102T AT94914102T ATE213155T1 AT E213155 T1 ATE213155 T1 AT E213155T1 AT 94914102 T AT94914102 T AT 94914102T AT 94914102 T AT94914102 T AT 94914102T AT E213155 T1 ATE213155 T1 AT E213155T1
Authority
AT
Austria
Prior art keywords
polypeptide
leee
factor
preparation
hirudo medicinalis
Prior art date
Application number
AT94914102T
Other languages
English (en)
Inventor
Moshe M Werber
Elisha P Zeelon
Avigdor Levanon
Rachel Guy
Arie Goldlust
Meir Rigbi
Amos Panet
Meir Fischer
Original Assignee
Bio Technology General Corp
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp, Yissum Res Dev Co filed Critical Bio Technology General Corp
Application granted granted Critical
Publication of ATE213155T1 publication Critical patent/ATE213155T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94914102T 1993-04-09 1994-04-08 Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis ATE213155T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4580493A 1993-04-09 1993-04-09
PCT/US1994/003918 WO1994023709A1 (en) 1993-04-09 1994-04-08 Production of recombinant factor xa inhibitor of leech hirudo medicinalis

Publications (1)

Publication Number Publication Date
ATE213155T1 true ATE213155T1 (de) 2002-02-15

Family

ID=21939978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94914102T ATE213155T1 (de) 1993-04-09 1994-04-08 Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis

Country Status (8)

Country Link
US (1) US5801017A (de)
EP (1) EP0693925B1 (de)
JP (1) JPH08510903A (de)
AT (1) ATE213155T1 (de)
AU (1) AU6630294A (de)
DE (1) DE69429858D1 (de)
IL (1) IL109258A0 (de)
WO (1) WO1994023709A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ270194A (en) * 1994-01-07 1996-05-28 Ciba Geigy Ag Hirustasin, a serine protease inhibitor from hirudo medicinalis
DE4440892A1 (de) * 1994-11-17 1996-05-23 Gruenenthal Gmbh Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
GB9930659D0 (en) * 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
US7618799B2 (en) 2007-01-31 2009-11-17 Dow Global Technologies Inc Bacterial leader sequences for increased expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
US4742004A (en) * 1984-08-27 1988-05-03 Bio-Technology General Corp. Method for producing enzymatically active eucaryotic sod in bacteria
EP0209061B1 (de) * 1985-07-17 1994-01-12 Hoechst Aktiengesellschaft Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel
NO170430C (no) * 1986-09-18 1992-10-14 Pennsylvania Hospital Fremgangsmaate for fremstilling av et protein som har antikoagulerende og anti-metastatiske egenskaper
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86856A0 (en) * 1988-06-24 1988-11-30 Yissum Res Dev Co Bovine xa factor and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
WO1994023709A1 (en) 1994-10-27
EP0693925B1 (de) 2002-02-13
DE69429858D1 (de) 2002-03-21
AU6630294A (en) 1994-11-08
IL109258A0 (en) 1994-07-31
JPH08510903A (ja) 1996-11-19
US5801017A (en) 1998-09-01
EP0693925A1 (de) 1996-01-31
EP0693925A4 (de) 1998-08-26

Similar Documents

Publication Publication Date Title
DK0423302T3 (da) Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner
EP0722461A4 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
DK1114062T3 (da) Modificeret E. coli-enterotoksin II-signalpeptid og en mikroorganisme, som eksprimerer et fusionsprotein af peptidet og et heterologt protein
ES8306797A1 (es) Un metodo para producir un polipeptido.
KR880007734A (ko) 폴리펩타이드 유도체
CA2341081A1 (en) Cloning and expression of microbial phytase
BR9406998A (pt) Construção de DNA vetor de expressão recombinante célula processo para produzir uma enzima demonstrando atividade proteolítica enzima enzima com atividade protease preparação de enzima e uso de uma enzima
DK0397420T3 (da) Enzymatisk fjernelse af en aminoterminal proteinsekvens
KR970700766A (ko) 다중변이체 il-3 조혈 융합 단백질(multivariant il-3 hematopoiesis fusion protein)
RO91186B (ro) Procedeu pentru prepararea unor peptide cu actiune asupra functiei glandei pituitare
GB8914122D0 (en) Polypeptide expression
BR9802403A (pt) Proteìna tendo atividade transglutaminase, dna, transformante, e, processo para produzir uma proteìna tendo uma atividade transglutaminase.
DE59509642D1 (de) Verfahren zur modifizierung der stabilität von antikörpern
KR920016464A (ko) 재조합 단백질의 개선된 활성화 방법
BR0012265A (pt) Fator estimulante de colÈnia de granulócitos humano modificado e processo para produzir o mesmo
ATE213155T1 (de) Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis
AU7873798A (en) N-terminally extended proteins expressed in yeast
DE69328992D1 (de) Mutanten von menschlichem Antithrombin III
WO1994003601A8 (en) Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
EP2085467A3 (de) Lutzomyia Longipalpis-Polypeptide und Verwendungsverfahren
EP0422217A4 (en) Human recombinant placental ribonuclease inhibitor and method of production
IL162133A0 (en) Method of increasing protein expression, proteins and polynucleotides
EP0750040A3 (de) Varianten des Makrophagen-stimulierendes-Proteins und Verfahren zur ihrer Herstellung
ATE358682T1 (de) Klonierte rezeptoren des glukagon-ähnlichen peptids-2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties